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A B S T R A C T
Introduction: Visfatin is a protein which belongs to the adiponectines, and
exhibits insulinomimetic properties. A high concentration of visfatin may be
directly related to an ongoing inflammatory process in the body. The aim of this
study was to assess changes in the concentration of visfatin in relation to the
intensity of alcohol craving and selected clinical characteristics in patients with
alcohol dependency.
Materials and methods: The thirty-seven males enrolled in the study had been
hospitalised due to alcohol dependence in the addiction treatment unit. In the first
week and after four weeks of treatment, clotted blood samples were obtained to
determine the concentration of visfatin and other biochemical parameters. Next,
patients were divided into two groups – group 1 with a decrease and group 2 with
an increase in the concentration of visfatin during the four weeks of treatment.
The study used a socio-demographic and clinical scale, the Short Alcohol
Dependence Data questionnaire (SADD) and an analogue alcohol craving scale.
Additionally, the study considered measurements of waist-to-hip circumference
ratio (WHR) and biochemical blood parameters.
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Visfatin is an adiponectin and plays an important
role in the regulation of inflammatory, metabolic and
immunological processes [1]. The role of visfatin in
the pathogenesis of obesity, insulin resistance,
metabolic syndrome, dyslipidemia, and related
cardiovascular complications has attracted consider-
able scientific interest in recent years [2]. Adiponec-
tines are also involved in the pathogenesis of chronic
liver disease caused by non-alcoholic fatty liver
disease and the viral hepatitis. They sustain the
inflammatory processes and enhance periportal
fibrosis [3].
Similar pathological processes occur in alcohol
abusers, who commonly exhibit an abnormal
metabolism of carbohydrates and lipids including
insulin resistance and hyperlipidaemia [4, 5]. Visfatin
concentration, and also leptin concentration, is
higher in obese and diabetic individuals. It is related
to the body fat tissue content [6, 7]. These observa-
tions are confirmed by FINRISK study which
showed that alcohol consumption increases the risk
of obesity [8]. Measurement of the changes in
Results: There was a statistically significant difference between group 1 and
group 2 in the concentration of visfatin (35.5 ng/ml vs 146 ng/ml) after four weeks
of inpatient alcohol dependence treatment.
Discussion: Perhaps different pathophysiological processes were taking place
(including inflammatory response) in patients with high and low visfatin
concentration in the initial stage of the trial.
Conclusions: The dynamic of change in the concentration of visfatin during four
weeks of abstinence is not associated with a reduction in craving for alcohol at the
time and is associated with alcohol drinking and liver functioning.
© 2015 Institute of Psychiatry and Neurology. Production and hosting by
Elsevier Sp. z o.o. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Słowa kluczowe:
wisfatyna
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S T R E S Z C Z E N I E
Wstęp: Wisfatyna jest białkiem (adipokiną), które wykazuje właściwości
insulinomimetyczne. Wysokie stężenie wisfatyny może być związane
z toczącym się w organizmie procesem zapalnym. Celem badań była ocena
zmian stężenia wisfatyny w odniesieniu do doświadczania głodu alkoholowego
i wybranych zmiennych klinicznych u osób uzależnionych od alkoholu.
Materiał i metody: W badaniu uczestniczyło 37 mężczyzn hospitalizowanych
z powodu uzależnienia od alkoholu. W pierwszym oraz czwartym tygodniu
leczenia pobrano krew do oznaczeń stężenia wisfatyny i innych parametrów
biochemicznych. Badane osoby zostały podzielone na dwie grupy – grupa 1 ze
spadkiem i grupa 2 ze wzrostem stężenia wisfatyny podczas czterech tygodni
hospitalizacji. U badanych oceniono zmienne socjodemograficzne, kliniczne,
głębokość uzależnienia od alkoholu (SADD), nasilenie głodu alkoholowego
(skala analogowa 0-10) oraz WHR (waist-to-hip circumference ratio) i parametry
biochemiczne krwi.
Wyniki: Wykazano znamienną statystycznie różnicę w stężeniu wisfatyny między
grupą 1 a grupą 2 (35,5 ng/ml vs 146 ng/ml) po 4 tygodniach leczenia odwykowego.
Dyskusja: Prawdopodobnie u pacjentów z wysokim i niskim stężeniem wisfatyny
w początkowym etapie leczenia (abstynencji) zachodziły odmienne procesy
patofizjologiczne (w tym mniej lub bardziej zaznaczona odpowiedź zapalna).
Wnioski: Dynamika zmian stężenia wisfatyny podczas co najmniej czterech
tygodni abstynencji nie jest związana z redukcją głodu alkoholowego w czasie,
lecz ze spożywaniem alkoholu i funkcją wątroby.
© 2015 Institute of Psychiatry and Neurology. Production and hosting by
Elsevier Sp. z o.o. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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biochemical marker of the metabolic processes
occurring in alcohol dependent persons (both during
acute excessive alcohol intake and during the
treatment of alcohol dependency, abstinence, and
recovery) [9]. Studies indicate that appetite-regulating
peptides have influence on the feeling of alcohol
craving [10]. For instance, studies have shown an
association between insulin concentrations and the
results of the severity of craving among actively
drinking individuals, what means that insulin may be
involved in the processes of neurobiological craving
for alcohol and addiction [9]. Thus, it can be expected
that the concentration of visfatin as a protein that
compensates adjustment of insulin carbohydrate [11]
may directly or indirectly result in the perception of
craving.
Visfatin is adiponectin the features of which we are
only just beginning to understand. However, the
knowledge about this protein and metabolic process-
es in which it participates acquired so far suggests that
it may become a notable marker of health problems
and the risk of relapse among alcohol dependent
persons. The pathophysiological role of visfatin may
be related to its insulin-like mechanism of action.
This may stimulate the activity of the hunger centre
which in turn enhances alcohol craving and also
promotes obesity.
The aim of this study was to assess changes in the
concentration of visfatin in relation to the intensity of
alcohol craving and selected clinical and anthropo-
metric characteristics in alcohol dependent patients.
The assessments were performed at the start of the
inpatient alcohol treatment and then again after four
weeks.
Materials and methods
The thirty-seven male patients hospitalised in the
addiction treatment unit due to alcohol dependence
(ICD-10) were enrolled in the study. The twenty-eight
males (mean age 31) from the general population
were examined as a control group. Subjects suffering
from alcohol withdrawal syndrome or metabolic
disorders such as diabetes were excluded from the
study.
The concentration of visfatin was measured in all
patients in the first and fourth week of hospitalisation
as it was in the control group. During four weeks of
treatment, an increase of the concentration of visfatin
was observed in some patients, and a decrease in
others. The question arises: Can changes in the
experience alcohol craving and clinical variables be
attributed to changes in visfatin concentration in the
time of abstinence?
The studied subjects were divided into two groups
depending on whether there was a decrease of the
visfatin concentration – group 1 of 21 inpatients (57%
of the study population, mean age 41) or an increase –
group 2 of 16 inpatients (43% and 38 respectively).
The patients were examined twice – once in the
first and once in the fourth week of hospitalisation.
The period of four weeks (between the first and
second examination) was chosen arbitrarily to assess
changes of the variables tested during therapy. All
permanent rehabilitation took no more than 8 weeks,
so tests would be repeated after 5–6 weeks, but in this
period of treatment the risk of premature therapy
finishing and stress before the end of hospitalisation
may increase.
Socio-demographic data (age, marital status,
employment) and information regarding severity of
alcohol craving and alcohol consumption during
30 days before the assessment were obtained from all
the subjects (some patients could participate in
detoxification therapy but it was not considered in
this study, also the time of subjects abstinence was not
taken into account). Alcohol craving was assessed
using an analogue scale (visual analogue scale) where
0 is “no alcohol craving” and 10 “extreme alcohol
craving”. This scale was selected due to its simplicity,
understanding (does not require complicated cultural
adaptation) and easiness in evaluation of intensity of
alcohol craving changes at the time. The severity of
alcohol dependence was assessed using SADD
(Short Alcohol Dependence Data questionnaire)
[12]. Higher scores indicate higher intensity of
dependence. The waist-to-hip circumference ratio
(WHR) was also measured. Values of >0.9 may
indicate abdominal obesity [13].
In the first week of treatment and after four weeks,
a clotted blood samples were obtained to determine the
concentration of visfatin (test EIA – Enzyme-linked
Immunosorbent Assay, USCN Life Science Inc.). The
blood samples were centrifuged at 48C and 3600 rev/
min. The serum obtained was stored at 808C. In the
first week of hospitalisation, the activity of alanine
aminotransferase (ALT), gamma-glutamyl transfer-
ase (GGTP), and concentration of glucose, triglycer-
ides, total cholesterol were evaluated.
Mann-Whitney U test, Fisher's exact test, and the
Wilcoxon test using SPSS 20 software were used for
D. Czarnecki et al. / Alcoholism and Drug Addiction 28 (2015) 173–181176statistical analysis of the results. Variables were
described by median and interquartile range (quar-
tile) due to the small number of respondents and the
asymmetry of variables distribution. The level of
statistical significance was considered at p  0.05.
The study was approved by the Ethics Committee
and funded by a university grant.
Results
The visfatin concentration in the first week and after
four weeks of hospitalisation
In the first step, we analysed the differences of
visfatin concentration between the group of alcohol
dependent inpatients in the first week and after four
weeks of hospitalisation and persons of the control
group (Fig. 1).
Fig. 1 showed that the highest concentration of
visfatin was in patients in the first week (98.0 ng/ml),
a lower level in patients in the fourth week (near
60 ng/ml) and the lowest in the control group (near
43 ng/ml). We observed a statistically significant
difference in the concentration of visfatin between
two trials, specifically in subjects in the first week and
those from the control group (p < 0.05).
Observation of a decrease (group 1) or an increase
(group 2) of visfatin concentration during the four-
week hospitalisation
In the evaluation of obtained results, it turned out
that in the part of subjects where the concentration of
visfatin was changed, in some it was higher and in
others lower (between the first and second trial). This
was the reason for the division of the studied
population into group 1 and group 2.
Fig. 1. Comparison of visfatin concentration between the groups of inpatient alcohol dependence treatment in the first week of
hospitalisation (n = 37), after four weeks of hospitalisation (n = 37) and control group (n = 28)
Mann-Whitney U test, where # p  0.05
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both groups (1 and 2) had similar visfatin concentra-
tion at the beginning of treatment (p = 0.141). The
change in the visfatin concentration was a statistically
significant in both groups after the four-week
treatment and there was a statistically significant
difference in visfatin concentration between both
groups in the fourth week of hospitalisation (35.5 ng/
ml vs 146 ng/ml).
The demographic data of two groups of patients
The demographic data of group 1 and 2 are
shown in Table I. Data indicate that subjects from
group 2 with an increased visfatin concentration
compared to the control group were more fre-
quently unemployed (78.6% and 37.5% respective-
ly) and more frequently single (55.6% and 25%
respectively).
The clinical characteristics of two groups of patients
The clinical data of group 1 and 2 are shown in
Table II. It illustrates age and clinical characteristics
(severity of dependence, intensity of alcohol craving,
laboratory indices, and WHR) of each of the two
patient groups.
We observed (Table II) that between the subjects
from group 1 with a decreased visfatin concentration
and those from group 2 with an increased visfatin
concentration there was no a statistically significant
differences concerning characteristics such as average
age (41 vs 38.8), duration of alcohol dependence
(10 years vs 10 years), SADD scores (21 vs 24),
triglycerides concentration (131 mg/dL vs 118.5 mg/
dL), total cholesterol concentration (226 mg/dL vs
229 mg/dL), and WHR at the beginning (1.0 vs 1.0)
and after four weeks of treatment (0.94 vs 0.97). In the
individuals from both groups the intensity of alcohol
Fig. 2. Comparison of visfatin concentration between the two groups of subjects – with a decreased (group 1) and with an increased
visfatin concentration (group 2) during the four-week inpatient alcohol dependence treatment
Dark colour means the first week of hospitalisation, bright – re-examination after four weeks of hospitalisation
Wilcoxon test, where * p  0.001; Mann-Whitney U test, where # p  0.05
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beginning (7.0 vs 6.5) and at the end (0.0 vs 0.0) of
treatment.
There was a statistically significant reduction in
the alcohol craving intensity in both groups after the
treatment (p  0.05). The average alanine aminotrans-
ferase (ALT) concentration was higher in group 1
(40 m/L vs 25 m/L). Similarly, the gamma-glutamyl
transferase (GGTP) concentration was higher in group
1 (79 mg/dL vs 40 mg/dL). A statistically significant
reduction of WHR during the treatment was observed
in both groups (1.0 vs 0.94 and 1.0 vs 0.97, respectively).
Ninety percent of patients with a reduced visfatin
concentration during the treatment (group 1), and 50%
Table I
Socio-demographic characteristics of each of the three patient groups (decreased visfatin concentration, increased visfatin
concentration and control) during the four-week inpatient alcohol dependence treatment
Socio-demographic characteristics Group 1 (n = 21) Group 2 (n = 16) Control group (n = 27–28)
Place of residence
Rural 4 (19.0%) 2 (12.5%) 3 (10.7%)
Urban 17 (81.0%) 14 (87.5%) 25 (89.3%)
Marital status
Married 12 (57.1%) 4 (25.0%) 15 (55.6%)
Single 9 (42.9%) 12 (75.0%) 12 (44.4%)
Source of income
Unemployed 6 (28.6%) 6 (37.5%) 5 (17.8%)
Employed 13 (61.9%) 6 (37.5%) 22 (78.6%)**
Pension 2 (9.5%) 4 (25.0%) 1 (3.6%)*
Group 1 – subjects with decreased concentration of visfatin during the four-week alcohol dependence treatment.
Group 2 – subjects with increased concentration of visfatin during the four-week alcohol dependence treatment.
Fisher's exact test, a statistically significant difference between: group 2 vs control group, where * p  0.05 and ** p  0.01.
Table II
Clinical characteristics of the groups of subjects with a decreased concentration of visfatin (group 1) and an increased concentration of
visfatin (group 2) during the four-week inpatient alcohol dependence treatment
Clinical characteristics Group 1 (n = 21) Group 2 (n = 16)
Quartiles Quartiles
M I III M I III
Age (years) 41.00 35.63 50.50 38.79 32.50 51.25
Duration of dependence (years) 10.00 5.50 16.50 10.00 6.25 12.00
Intensity of alcohol craving (scale 0–10) I 7.00** 5.00 8.00 6.50** 3.50 9.75
Intensity of alcohol craving (scale 0–10) II 0.00 0.00 4.50 0.00 0.00 8.00
SADD (scores) I 21.00 17.75 26.50 24.00 20.00 27.00
Consumption of alcohol during 30 days prior
to hospitalisation (number %)
Yes 19 (90.5%) 8 (50%)##
No 2 (9.5%) 8 (50%)
ALT (U/L) I 40.00 25.50 58.50 25.00 18.50 36.25
GGTP (U/L) I 79.00# 44.50 136.50 40.00# 27.00 68.00
Serum glucose (mg%) I 87.00 82.50 93.50 89.00 85.00 95.50
Triglycerides (mg/dL) I 131.00 100.50 178.50 118.50 96.75 198.00
Total cholesterol (mg/dL) I 226.00 197.50 278.50 229.00 197.25 252.50
WHR I 1.00* 0.91 1.00 1.00** 0.90 1.00
WHR II 0.94* 0.90 1.00 0.97** 0.90 0.99
I – assessment at the first week of hospitalisation, II – re-assessment at the fourth week of hospitalisation.
Wilcoxon test, where * p = 0.099, ** p  0.05; Mann-Whitney U test or Fisher's exact test, where # p  0.05, ## p  0.01.
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(group 2) consumed alcohol during 30 days before
hospitalisation.
Discussion
The study showed that subjects had higher visfatin
concentration in the first week of treatment than after
four weeks, and also higher than in the control group.
But the analysis of outcomes showed that in some
subjects a decrease and in the others an increase in
visfatin concentration followed during the four-week
hospitalisation (four-week abstinence). It was very
interesting which changes in the clinical character-
istics were connected with the decreasing (group 1) or
increasing trend (group 2) of visfatin concentration
during the treatment. In both groups there was
a statistically significant change of visfatin concen-
tration during the treatment, and between group
1 and group 2 there was a statistically significant
difference of visfatin concentration only in the fourth
week of treatment. The concentration of visfatin,
when studied subjects at the beginning of treatment
were compared with the control group was lower in
males from the control group. These males consumed
less alcohol, were younger and characterised by
a lower WHR. The concentration of visfatin was also
lower in the subjects after four weeks of abstinence.
Jurdana et al. found that significant predictors of
visfatin concentration were low physical activity
among men and also an activity of C-reactive protein.
The latter is independent of gender [6].
An association between visfatin and C-reactive
protein levels may explain the phenomenon of
different trends of visfatin concentration in alcohol
dependent subjects during their four-week inpatient
treatment. Perhaps different pathophysiological pro-
cesses were taking place (including inflammatory
response) in the patients with high (decreasing trend
during the treatment) and low (increasing trend)
visfatin concentration in the initial stage of the trial.
Heng-cai et al. in research on rats showed that
visfatin concentration was higher by strong exposure
to ethanol and visfatin concentration was correlated
positively with visceral adipocyte tissues [14]. Accord-
ing to Ozkaya et al. the concentration of visfatin in
plasma is associated with body mass, metabolic
syndrome or diabetes [15], but according to different
study there is no correlation between visfatin
concentration and metabolic or anthropometric
variables [16].
The studied subjects (from group 1 and 2) showed
similar changes in the clinical characteristics during
the four-week inpatient treatment. There was
decrease in WHR (waist-to-hip circumference ratio)
and intensity of alcohol craving. None of the groups
of patients showed any statistically significant differ-
ences in WHR or alcohol craving, either at the start of
alcohol dependence treatment or after four weeks of
the treatment. In the group of subjects with an
increased concentration of visfatin, there was no
increase in WHR. This differs from the results of
other studies indicating a significant positive link
between visfatin concentration and body fat percent-
age [17]. As researches showed, an increase of visfatin
concentration is observed in metabolic syndrome
(where anthropometric indices are higher) [18] and in
diabetes type II [3].
The literature suggests that a high concentration of
visfatin may be directly related to an ongoing
inflammatory process in the body [3]. However, as
other authors suggest, the concentration of circulat-
ing visfatin and liver visfatin mRNA level are reduced
in patients with hepatitis [17]. Subsequent analysis
showed that the subjects with low concentration of
visfatin at the beginning of treatment differ from
those with a higher concentration of visfatin
[17]. They (the first ones) characterised with lower
alcohol consumption and lower liver enzymes activity
during 30 days before the trial. There is decreased
concentration of visfatin in blood serum in patients
with liver cirrhosis.
Heng-cai et al. showed that changes of visfatin,
leptin and adiponectin can be independent of alcohol
related liver injury [14]. Visfatin concentration seems
not to be related to insulin resistance but rather to the
reduced glucose metabolism (when compared to
healthy people), for example in liver cirrhosis
[17]. The concentration of visfatin is positively
correlated with the blood ketone index and NADH
++H+ generation [17].
According to Wu and Cederbaum [19], the
reduced form of nicotinamide adenine dinucleotide
(NAD++H+) is generated in a cytoplasm of
hepatocytes during a transformation of ethyl alcohol
into acetate. This may result in the suppression of
“mitochondrial oxidation”, over-production of tri-
glycerides and lactate in the liver, and also lead to an
excess of free fatty acids [19, 20]. It is likely that
visfatin stimulates insulin, interleukin-6 (IL-6),
tumour necrosis factor a (TNFa) secretion, and also
induces the synthesis of nicotinamide adenine
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dependent subjects had higher insulin and glucose
levels in response to beer consumption than those not
dependent [21].
Zilkens et al. confirmed that there is
a proportional increase in insulin concentration in
blood serum and homeostatic model assessment
(HOMA) index values to the amount of consumed
alcohol [22].
A statistically significant positive correlation
between concentration of insulin and intensity of
alcohol craving (in subjects actively consuming
alcohol) has also been demonstrated in other studies.
This indicates that insulin may be involved in
neurobiological processes of alcohol craving and
alcohol dependence [9, 23].
Based on the analysis of data obtained in this
study, it can be assumed there is an association
between the serum concentration of visfatin and
alcohol craving. This problem requires further
research because of the importance of alcohol craving
in promoting relapse of alcohol drinking behaviour.
Clinical benefits: Evaluation of concentration of
visfatin in alcohol dependent patients attending an
addiction treatment unit may be an important
predictor of biochemical changes occurring due to
changes in anatomical and secretory adipocytes.
Thus, the assessment of changes in the concentration
of visfatin will help evaluate the risk of obesity,
insulin resistance, occurrence of inflammatory pro-
cesses and fatty liver disease [24, 25] in order to reduce
health damage. However, according to research the
above-mentioned assessment did not detect patient
exposure to alcohol craving effectively.
Limitations of research: Small group of respond-
ents, lack of assessment of selected biochemical
marks in the second stage of the study, no application
of an additional questionnaire to measure the severity
of alcohol craving and verification of patients in
terms of psychotropic medications, and in terms of
other factors such as stress and social relations that
could have an impact on the willingness for alcohol
consumption.
Conclusions
It was found that almost 57% of studied subjects
had a decrease and 43% an increase in the
concentration of visfatin after the four-week alcohol
dependence inpatient treatment.
There was a significant reduction in the intensity of
alcohol craving during the four-week alcohol depen-
dence inpatient treatment in both groups – with
a decreased and an increased visfatin concentration.
Subjects with a decreased concentration of visfatin
consumed alcohol more often during 30 days prior to
hospitalisation and had higher activity of GGTP
when compared to subjects with an increased
concentration of visfatin after the four-week alcohol
dependence inpatient treatment. Higher GGTP
activity suggests more advanced hepatitis.
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